EBS News and Press, Emergent Biosolutions Inc. From 01/03/21

Vaxart as a COVID-19 vaccine play had surged after upbeat news in June, but is now at lower valuations. Still, the stock price is on a net one-year uptrend, as a result of the biotech's quite unique treatment being developed against the coronavirus. Moreover, the company's image h...

GAITHERSBURG, Md. and NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) and Mount Sinai Health System today announced initiation of the clinical program to evaluate Emergent’s COVID-19 Human Hyperimmune Globulin (COVID-HIG) product candidate in the first o...

Coronavirus vaccine makers have quickly turned to a network of smaller, lesser-known manufacturers to mount an unprecedented effort to produce their shots at a record pace, WSJ reports.While new mRNA technology makes industrialization easier than a traditional vaccine - since manufacturers do...

As of Dec. 7, the Nasdaq had a P/E ratio of 32.7 while the Russell 2000 was at 17.1. In the fourth quarter through Dec. 7, the Nasdaq has returned 10.5% while the Russell 2000 and Russell Micro-Cap indices have returned 25.8% and 27.6%. we believe now is the time to focus your att...

Are These The Best Biotech Stocks To Watch Next Week? Looking for the best biotech stocks to buy may appear to be not too different from gambling for some. That’s because trying to bet on which company’s vaccine candidates are more likely to work can often feel lik...

Gaithersburg, MD-based Emergent BioSolutions ([[EBS]] -2.6%) will be featured on a 60 Minutes segment this Sunday, November 15, on Operation Warp Speed. The company is producing COVID-19 vaccines for Johnson & Johnson ([[JNJ]] +0.0%) and AstraZeneca ([[AZN]] -2.3%). Specifically, it is sc...

Shareholders of vaccine and antibody therapy specialist Emergent BioSolutions (NYSE: EBS) were feeling a bit queasy on Friday afternoon. That day, the company's stock fell by almost 4.9% after the release of the latest quarterly earnings. In its fiscal third quarter of 2020, Eme...

The following slide deck was published by Emergent BioSolutions Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Emergent BioSolutions Inc. 2020 Q3 - Results - Earnings Call Presentation

Emergent BioSolutions Inc. (EBS) Q3 2021 Earnings Conference Call November 05, 2020 05:00 PM ET Company Participants Bob Burrows - Vice President, Investor Relations Bob Kramer - President and Chief Executive Officer Rich Lindahl - Chief Financial Officer Syed Husain - Senior Vice President &...

Emergent Biosolutions (EBS): Q3 Non-GAAP EPS of $2.19 beats by $0.04; GAAP EPS of $0.73 misses by $1.03.Revenue of $385.2M (+23.5% Y/Y) misses by $53.31M.FY2020 guidance: Total revenues of $1,520M-$1,580M from previous guidance of $1,500M-$1,600M vs consensus of $1.52B ; Adjusted net income o...